We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.63%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$659M
AUM Growth
-$194M
Cap. Flow
-$205M
Cap. Flow %
-31.16%
Top 10 Hldgs %
43.01%
Holding
164
New
28
Increased
30
Reduced
27
Closed
56

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$15.1M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
NMTR
9 Meters Biopharma
NMTR
+$9.54M
5
MRK icon
Merck
MRK
+$8.77M

Top Sells

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.22M
4
RXDX
Ignyta, Inc.
RXDX
+$9.19M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 75.21%
2 Technology 4.55%
3 Financials 1.71%
4 Communication Services 1.32%
5 Consumer Discretionary 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$65.8M 9.99%
750,000
-1,200,000
-62% -$110M
MRK icon
2
Merck
MRK
$322B
$31.6M 4.8%
607,840
+162,440
+36% +$8.77M
SHPG
3
DELISTED
Shire pic
SHPG
$29.4M 4.46%
196,500
+110,000
+127% +$15.1M
CELG
4
DELISTED
Celgene Corp
CELG
$28.5M 4.32%
319,000
+10,000
+3% +$960K
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$27.8M 4.21%
1,845,704
+745,704
+68% +$11.3M
VTRS icon
6
Viatris
VTRS
$20.4B
$23.6M 3.59%
574,000
-182,449
-24% -$7.78M
PFE icon
7
Pfizer
PFE
$143B
$20.9M 3.18%
621,860
+210,800
+51% +$7.25M
GSK icon
8
GSK
GSK
$104B
$19.5M 2.97%
400,000
+40,000
+11% +$1.86M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.57B
$18.4M 2.8%
248,997
-136,000
-35% -$9.07M
BIIB icon
10
Biogen
BIIB
$30B
$17.8M 2.7%
65,000
-9,200
-12% -$2.86M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$78.5B
$14.3M 2.17%
+41,500
New +$14.4M
QQQ icon
12
PUT
Invesco QQQ Trust
QQQ
$453B
$12.8M 1.94%
+80,000
New +$13.2M
NMTR
13
DELISTED
9 Meters Biopharma
NMTR
$12.3M 1.86%
+49,025
New +$9.54M
CLSD
14
DELISTED
Clearside Biomedical
CLSD
$11.1M 1.68%
68,667
+38,667
+129% +$4.71M
CLLS
15
Cellectis
CLLS
$277M
$10.7M 1.62%
339,367
– –
AGN
16
DELISTED
Allergan plc
AGN
$10.1M 1.53%
60,000
– –
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$10.1M 1.53%
745,197
+197,500
+36% +$2.42M
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
$9.14M 1.39%
82,000
-38,000
-32% -$4.54M
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$8.87M 1.35%
168,000
+10,000
+6% +$583K
ADMS
20
DELISTED
Adamas Pharmaceuticals
ADMS
$8.02M 1.22%
335,500
+195,000
+139% +$6.15M
LJPC
21
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.74M 1.18%
260,000
+35,000
+16% +$1.13M
ALDX icon
22
Aldeyra Therapeutics
ALDX
$92.9M
$7.57M 1.15%
1,009,131
-35,000
-3% -$266K
MLNX
23
DELISTED
Mellanox Technologies, Ltd.
MLNX
$7.3M 1.11%
100,279
+26,833
+37% +$1.81M
IMMU
24
DELISTED
Immunomedics Inc
IMMU
$7.01M 1.06%
480,000
+250,000
+109% +$4.08M
VKTX icon
25
Viking Therapeutics
VKTX
$3.7B
$6.96M 1.06%
1,592,416
-552,884
-26% -$3.06M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sphera Funds Management held 164 positions worth $659M, down 23% from $852M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Sphera Funds Management withdrew a net $205M in Q1 2018, closing 56 positions and reducing 27 holdings. Its most notable exit was Cellcom Israel, Ltd., an estimated $14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 59% a quarter earlier, followed by Technology and Financials.

Against the trend, Sphera Funds Management opened a new position in Regeneron Pharmaceuticals worth $14.3M.

  • Sphera Funds Management's largest Q1 2018 buy was Regeneron Pharmaceuticals: 41,500 shares worth $14.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2018, an estimated $15.1M increase.
  • Sphera Funds Management's biggest Q1 2018 reduction was Sarepta Therapeutics, cutting an estimated $9.07M.
  • Sphera Funds Management fully exited Cellcom Israel, Ltd. in Q1 2018, selling an estimated $14M.
  • Sphera Funds Management's ten largest holdings make up 43% of its $659M portfolio in Q1 2018.
  • Sphera Funds Management opened 28 new positions and closed 56 in Q1 2018.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $659M.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.